Adenocarcinomas | Squamous cell carcinomas | Small cell carcinomas | |
---|---|---|---|
N = 646 (100.0%) | N = 524 (100.0%) | N = 233 (100.0%) | |
Sex | |||
Male | 440 (68.1%) | 474 (90.5%) | 191 (82.0%) |
Female | 206 (31.9%) | 50 (9.5%) | 42 (18.0%) |
Age group | |||
< 50 | 89 (13.8%) | 21 (4.0%) | 19 (8.1%) |
50–59 | 186 (28.8%) | 118 (22.5%) | 68 (29.2%) |
60–69 | 162 (25.1%) | 142 (27.1%) | 57 (24.5%) |
70–79 | 163 (25.2%) | 173 (33.0%) | 70 (30.0%) |
≥ 80 | 46 (7.1%) | 70 (13.4%) | 19 (8.1%) |
Comorbid conditionsa | |||
Chronic obstructive pulmonary disease | 130 (20.1%) | 161 (30.7%) | 54 (23.2%) |
Peripheral vascular disease | 86 (13.3%) | 77 (14.7%) | 28 (12.0%) |
Congestive heart failure | 54 (8.4%) | 75 (14.3%) | 23 (9.9%) |
Charlson Comorbidity Index | |||
0 | 319 (49.4%) | 195 (37.2%) | 107 (45.9%) |
1 | 159 (24.6%) | 157 (30.0%) | 61 (26.2%) |
2 | 84 (13.0%) | 79 (15.1%) | 31 (13.3%) |
≥ 3 | 62 (9.6%) | 75 (14.3%) | 24 (10.3%) |
Unknown | 22 (3.4%) | 18 (3.4%) | 10 (4.3%) |
Topography | |||
Main bronchus | 22 (3.4%) | 59 (11.3%) | 24 (10.3%) |
Upper lobe | 341 (52.8%) | 254 (48.5%) | 109 (46.8%) |
Middle lobe | 26 (4.0%) | 14 (2.7%) | 12 (5.1%) |
Lower lobe | 153 (23.7%) | 133 (25.4%) | 43 (18.5%) |
Overlapping lesion | 33 (5.1%) | 25 (4.8%) | 26 (11.2%) |
Not specified | 71 (11.0%) | 39 (7.4%) | 19 (8.1%) |
Stage | |||
Non-small cell – Surgery | |||
1 | 75 (41.0%) | 52 (37.4%) | – |
2 | 18 (9.8%) | 39 (28.1%) | – |
3 | 62 (33.9%) | 45 (32.4%) | – |
4 | 26 (14.2%) | 2 (1.4%) | – |
Unknown | 2 (1.1%) | 1 (0.7%) | – |
Non-small cell – No surgery | |||
1 | 8 (1.7%) | 16 (4.2%) | – |
2 | 2 (0.4%) | 5 (1.3%) | – |
3 | 87 (18.8%) | 138 (36.0%) | – |
4 | 354 (76.5%) | 198 (51.7%) | – |
Unknown | 12 (2.6%) | 26 (6.8%) | – |
Small cell – Surgery | |||
Limited | – | – | 6 (85.7%) |
Extensive | – | – | 1 (14.3%) |
Unknown | – | – | 0 (0.0%) |
Small cell – No surgery | |||
Limited | – | – | 61 (27.1%) |
Extensive | – | – | 155 (68.9%) |
Unknown | – | – | 9 (4.0%) |
Diagnostic mode | |||
Incidental diagnosis | 76 (11.8%) | 57 (10.9%) | 19 (8.1%) |
Pulmonary symptoms | 360 (55.7%) | 350 (66.8%) | 143 (61.4%) |
Other symptoms | 169 (26.2%) | 96 (18.3%) | 63 (27.0%) |
Surveillance of high-risk patients | 29 (4.5%) | 12 (2.3%) | 2 (0.9%) |
Unknown | 12 (1.9%) | 9 (1.7%) | 6 (2.6%) |
Tobacco smoking | |||
Current smoker | 274 (42.4%) | 224 (42.7%) | 123 (52.8%) |
Former-smoker | 227 (35.1%) | 248 (47.3%) | 89 (38.2%) |
Never smoker | 85 (13.2%) | 15 (2.9%) | 1 (0.4%) |
Unknown | 60 (9.3%) | 37 (7.1%) | 20 (8.6%) |
Absence of treatment | |||
Yes | 78 (12.1%) | 84 (16.0%) | 34 (14.6%) |
Unknown | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |